Toll-like receptors: Link between "danger" ligands and plaque instability

Current Drug Targets

Volumn 10, Issue 6, 2009, Pages 513-518

  Balogh, Sándor ^a   Kiss, István ^b   Csaszar, Albert ^c  

^a UNIVERSITY OF SZEGED   (Hungary)

^b Szent Imre Hospital   (Hungary)

^c State Health Center   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BACTERIAL ANTIGEN; CD36 ANTIGEN; HEAT SHOCK PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OXIDIZED LOW DENSITY LIPOPROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; VIRUS ANTIGEN;

ADAPTIVE IMMUNITY; APOPTOSIS; ARTERY RUPTURE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; DISEASE COURSE; HUMAN; INFECTION; INFLAMMATION; INNATE IMMUNITY; ISCHEMIA; KIDNEY ISCHEMIA; LIGAND BINDING; NONHUMAN; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RECEPTOR BINDING; REPERFUSION INJURY; REVIEW; SEPSIS; SIGNAL TRANSDUCTION;

ANIMALS; ATHEROSCLEROSIS; HUMANS; ISCHEMIA; LIGANDS; MODELS, BIOLOGICAL; REPERFUSION INJURY; TOLL-LIKE RECEPTORS;

EID: 68349143099     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945009788488387     Document Type: Review

References (59)

1. Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 1983; 50(2): 127-34.
2. Varnava AM, Mills PG, Davies MJ. Relationship between coronary artery remodeling and plaque vulnerability. Circulation 2002; 105(8): 939-43.
3. Friedman M. Pathogenesis of coronary thrombosis, intramural and intraluminal hemorrhage. Adv Cardiol 1970; 4: 20-46.
4. Smieja M, Gnarpe J, Lonn E, Gnarpe H, Olsson G, Yi Q, et al. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2003; 107(2): 251-7.
5. Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Mäkelä PH, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2(8618): 983-6.
6. Adam E, Melnick JL, Probtsfield JL, Petrie BL, Burek J, Bailey KR, et al. High levels of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis. Lancet 1987; 2(8554): 291-3.
7. Ishizaka N, Ishizaka Y, Takahashi E, Tooda E, Hashimoto H, Nagai R, et al. Association between hepatitis C virus seropositivity, carotid-artery plaque, and intima-media thickening. Lancet 2002; 359(9301): 133-5.
8. Petrakopoulou P, Kübrich M, Pehlivanli S, Meiser B, Reichart B, von Scheidt W, et al. Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function. Circulation 2004; 110(11 Suppl 1): II207-12.
9. Ludewig B, Krebs P, Scandella E. Immunopathogenesis of atherosclerosis. J Leukoc Biol 2004; 76(2): 300-6.
10. Stassen FR, Vega-Córdova X, Vliegen I, Bruggeman CA. Immune activation following cytomegalovirus infection: more important than direct viral effects in cardiovascular disease? J Clin Virol 2006; 35(3): 349-53.
11. Robertson AK, Hansson GK. T cells in atherogenesis: for better or for worse? Arterioscler Thromb Vasc Biol 2006; 26(11): 2421-32.
12. Björkbacka H. Multiple roles of Toll-like receptor signaling in atherosclerosis. Curr Opin Lipidol 2006; 17(5): 527-33.
13. Kawai T, Akira S. Pathogen recognition with Toll-like receptors. Curr Opin Immunol 2005; 17(4): 338-44.
14. Karin M, Lawrence T, Nizet V. Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 2006; 124(4): 823-35.
15. Nestle FO, Banchereau J, Hart D. Dendritic cells: On the move from bench to bedside. Nat Med 2001; 7(7): 761-5.
16. Wallet MA, Sen P, Tisch R. Immunoregulation of dendritic cells. Clin Med Res 2005; 3(3): 166-75.
17. Shigeoka AA, Holscher TD, King AJ, Hall FW, Kiosses WB, Tobias PS, et al. TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both MyD88-dependent and -independent pathways. J Immunol 2007; 178(10): 6252-8.
18. Johnsson C, Tufveson G, Wahlberg J, Hallgren R. Experimentally-induced warm renal ischemia induces cortical accumulation of hyaluronan in the kidney. Kidney Int 1996; 50(4): 1224-9.
19. Kim BS, Lim SW, Li C, Kim JS, Sun BK, Ahn KO, et al. Ischemia-reperfusion injury activates innate immunity in rat kidneys. Transplantation 2005; 79(10): 1370-7.
20. Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. J Exp Med 2005; 201(7): 1135-43.
21. Wu H, Chen G, Wyburn KR, Yin J, Bertolino P, Eris JM, et al. TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest 2007; 117(10): 2847-59.
22. Shishido T, Nozaki N, Yamaguchi S, Shibata Y, Nitobe J, Miyamoto T, et al. Toll-like receptor-2 modulates ventricular remodeling after myocardial infarction. Circulation 2003; 108(23): 2905-10.
23. Chong AJ, Shimamoto A, Hampton CR, Takayama H, Spring DJ, Rothnie CL, et al. Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart. J Thorac Cardiovasc Surg 2004; 128(2): 170-9.
24. Satoh M, Shimoda Y, Maesawa C, Akatsu T, Ishikawa Y, Minami Y, et al. Activated toll-like receptor 4 in monocytes is associated with heart failure after acute myocardial infarction. Int J Cardiol 2006; 109(2): 226-34.
25. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, et al. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 1999; 104(3): 271-80.
26. Sakata Y, Dong JW, Vallejo JG, Huang CH, Baker JS, Tracey KJ, et al. Toll-like receptor 2 modulates left ventricular function following ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2007; 292(1): H503-9.
27. Oyama J, Blais C Jr, Liu X, Pu M, Kobzik L, Kelly RA, et al. Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice. Circulation 2004; 109(6): 784-9.
28. Björkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004; 10(4): 416-21.
29. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 2004; 101(29): 10679-84.
30. Methe H, Kim JO, Kofler S, Weis M, Nabauer M, Koglin J. Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation 2005; 111(20): 2654-61.
31. Michelsen KS, Arditi M. Toll-like receptor signaling and atherosclerosis. Curr Opin Hematol 2006; 13(3): 163-8.
32. Björkbacka H. Multiple roles of Toll-like receptor signaling in atherosclerosis. Curr Opin Lipidol 2006; 17(5): 527-33.
33. Björkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004; 10(4): 416-21.
34. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 2004; 101(29): 10679-84.
35. Holloway JW, Yang IA, Ye S. Variation in the toll-like receptor 4 gene and susceptibility to myocardial infarction. Pharmacogenet Genom 2005; 15(1): 15-21.
36. Björkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, et al. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004; 10(4): 416-21.
37. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, et al. Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 2004; 101(29): 10679-84.
38. Mullick AE, Tobias PS, Curtiss LK. Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest 2005; 115(11): 3149-56.
39. Frantz S, Ertl G, Bauersachs J. Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nat Clin Pract Cardiovasc Med 2007; 4(8): 444-54.
40. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347(3): 185-92.
41. Labrum R, Bevan S, Sitzer M, Lorenz M, Markus HS. Toll receptor polymorphisms and carotid artery intima-media thickness. Stroke 2007; 38(4): 1179-84.
42. Weis M, Schlichting CL, Engleman EG, Cooke JP. Endothelial determinants of dendritic cell adhesion and migration: new implications for vascular diseases. Arterioscler Thromb Vasc Biol 2002; 22(11): 1817-23.
43. Bobryshev YV. Dendritic cells in atherosclerosis: current status of the problem and clinical relevance. Eur Heart J 2005; 26(17): 1700-4.
44. Zhang X, Niessner A, Nakajima T, Ma-Krupa W, Kopecky SL, Frye RL, et al. Interleukin 12 induces T-cell recruitment into the atherosclerotic plaque. Circ Res 2006; 98(4): 524-31.
45. Niessner A, Sato K, Chaikof EL, Colmegna I, Goronzy JJ, Weyand CM. Pathogen-sensing plasmacytoid dendritic cells stimulate cytotoxic T-cell function in the atherosclerotic plaque through interferon-alpha. Circulation 2006; 114(23): 2482-9.
46. Ohashi K, Burkart V, Flohé S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000; 164(2): 558-61.
47. Sasu S, LaVerda D, Qureshi N, Golenbock DT, Beasley D. Chlamydia pneumoniae and chlamydial heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/p42 mitogen-activated protein kinase activation. Circ Res 2001; 89(3): 244-50.
48. Xu Q. Infections, heat shock proteins, and atherosclerosis. Curr Opin Cardiol 2003; 18(4): 245-52.
49. Xu Q. Role of heat shock proteins in atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22(10): 1547-59.
50. Miller YI, Chang MK, Binder CJ, Shaw PX, Witztum JL. Oxidized low density lipoprotein and innate immune receptors. Curr Opin Lipidol 2003; 14(5): 437-45.
51. Boullier A, Friedman P, Harkewicz R, Hartvigsen K, Green SR, Almazan F, et al. Phosphocholine as a pattern recognition ligand for CD36. J Lipid Res 2005; 46(5): 969-76.
52. Greaves DR, Gordon S. Thematic review series: the immune system and atherogenesis. Recent insights into the biology of macrophage scavenger receptors. J Lipid Res 2005; 46(1): 11-20.
53. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002; 105(10): 1158-61.
54. Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, et al. Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001; 104(25): 3103-8.
55. Caligiuri G, Rottenberg M, Nicoletti A, Wigzell H, Hansson GK. Chlamydia pneumoniae infection does not induce or modify atherosclerosis in mice. Circulation 2001; 103(23): 2834-8.
56. Wright SD, Burton C, Hernandez M, Hassing H, Montenegro J, Mundt S, et al. Infectious agents are not necessary for murine atherogenesis. J Exp Med 2000; 191(8): 1437-42.
57. Methe H, Kim JO, Kofler S, Nabauer M, Weis M. Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes. Arterioscler Thromb Vasc Biol 2005; 25(7): 1439-45.
58. Yan ZQ, Hansson GK. Innate immunity, macrophage activation, and atherosclerosis. Immunol Rev 2007; 219: 187-203.
59. Vink A, de Kleijn DP, Pasterkamp G. Functional role for toll-like receptors in atherosclerosis and arterial remodeling. Curr Opin Lipidol 2004; 15(5): 515-21.